To further explore the new utility of this conventional biomarker, the AFP response (>20% decrease after initial therapy) was employed to predict the radiologic response and survival of HCC patients undergoing targeted chemotherapy.18, 19. This evidence concerns the gene AFP and hepatocellular carcinoma.